RAIN
Rain Therapeutics Inc. [RAIN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RAIN Stock Summary
In the News
RAIN Financial details
Company Rating
-
Market Cap
44.01M
Income
-71M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
63
Optionable
No
Shortable
Yes
Earnings
07 Mar 2024
P/E
-0.61
Forward P/E
-
PEG
0.26
P/S
-
P/B
0.65
P/C
-
P/FCF
-0.64
Quick Ratio
5.38
Current Ratio
5.58
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.03
EPS next Y
-
EPS next Q
-
EPS this Y
2.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-68.85%
-
-
-
-
SMA20
20%
SMA50
100%
SMA100
100%
Inst Own
-
Inst Trans
-
ROA
-87%
ROE
-82%
ROC
-1.13%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.82-11.32
52W High
-
52W Low
-
RSI
58
Rel Volume
0.02
Avg Volume
238.29K
Volume
5.96K
Perf Week
5.87%
Perf Month
18.97%
Perf Quarter
-16.38%
Perf Half Y
73.27%
-
-
-
-
Beta
0.273
-
-
Volatility
0.09%, 0.4%
Prev Close
-3.83%
Price
5.77
Change
-2.53%
Company Profile
- Volume Average 238.29K
- Market Capitalization 44.01M
- Employee 63
- CEO Mr. Avanish Vellanki M.B.A.
- Headquarters Newark,CA,US
- IPO Date 2021-04-23
-
Website
https://www.rainthera.com 
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
